Biomarin Pharmaceutical Aktie

Kaufen

Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

46,80 EUR -0,27 EUR -0,57 %

22:13:17

BMN

54,07 USD -0,08 USD -0,15 %

nachbörslich22:07:14

BTT

Biomarin Pharmaceutical jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.9,06 Mrd. EUR

KGV29,78Div. Rendite0,00%

WKN924801

ISINUS09061G1013

SymbolBMRN

Biomarin Pharmaceutical Aktien News

Sortieren:Datum Meistgelesen

29.06.23PR NewswireU.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A

22.06.23PR NewswireBioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis ...

04.05.23PR NewswireBioMarin to Participate in Bank of America 2023 Health Care Conference

26.04.23PR NewswireBioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues

13.04.23PR NewswireBioMarin to Host First Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, April 26, at 4:30pm ET

14.03.23PR NewswireBioMarin to Share Updated Data at 2023 American College of Medical Genetics and Genomics (ACMG) Meeting Demonstrating Commitment to Understanding Long-Term Benefit of VOXZOGO® in Children with Ach...

07.03.23PR NewswireFDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO® (vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 5

07.03.23PR NewswireBioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A

02.03.23PR NewswireBioMarin to Participate in Three Investor Conferences in March

27.02.23PR NewswireBioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business

14.02.23PR NewswireBioMarin to Participate Virtually at SVB Securities Global Biopharma Conference on February 16, 2023

07.02.23PR NewswireBioMarin to Host Fourth Quarter and Full-Year 2022 Financial Results Conference Call and Webcast on Monday, February 27, at 4:30 p.m. ET

08.01.23PR NewswireBioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™ in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Se...

04.01.23PR NewswireBioMarin to Present at 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, at 10:30 am PT /1:30 pm ET, in San Francisco, CA

03.01.23PR NewswireEuropean Medicines Agency Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2

28.11.22RSSForm 4 1048477

Biomarin Pharmaceutical News

Biomarin Pharmaceutical News: auf dieser Seite finden Sie alle Biomarin Pharmaceutical News und Nachrichten zur Biomarin Pharmaceutical Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Biomarin Pharmaceutical News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Biomarin Pharmaceutical News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.